UK biotech venture capital surged to a five-year high in Q2 2026, reaching £2.05 billion ($2.76 billion) according to figures from the BioIndustry Association. The report cited Isomorphic Labs’ £1.6 billion Series B as the primary driver of the quarter’s totals. Even excluding that landmark deal, UK companies raised £498 million ($669 million) in VC during the quarter—nearly double the year-ago level. BIA said seed rounds remained resilient, with early-stage companies opting for larger first financings. The funding pattern suggests a cautious rebound after prior fundraising stress, with the industry continuing to favor nearer-to-clinic evidence generation as investors pressure proof-of-demand timelines.